Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty - A randomized Controlled Trial.

Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T

The Journal of arthroplasty17 Jul 2015Cited by 42 (Europe PMC)

PMID26260784DOI10.1016/j.arth.2015.07.017PepBankPUB-26260784

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients after total hip arthroplasty, teriparatide had a significant effect on periprosthetic BMD loss.
In plain wordsIn patients after hip replacement, teriparatide had a significant effect on bone density loss around the implant.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePeriprosthetic BMD loss
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
For periprosthetic BMD loss, a significant effect of teriparatide was demonstrated, though its effect was similar to alendronate.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effect of teriparatide for the prevention of bone mineral density (BMD) loss after THA was compared with alendronate in a randomized controlled trial. Forty-eight patients were assigned to three groups, namely, the teriparatide, alendronate, and no medication groups.
Report a problemFND-2626078401
02HumanRandomized controlled trialEfficacy outcome
In patients after total hip arthroplasty, teriparatide had a similar effect on periprosthetic BMD loss to alendronate.
In plain wordsIn patients after hip replacement, teriparatide and alendronate had similar effects on bone density loss around the implant.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePeriprosthetic BMD preservation
Study
n: not reported in source
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
For periprosthetic BMD loss, a significant effect of teriparatide was demonstrated, though its effect was similar to alendronate.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effect of teriparatide for the prevention of bone mineral density (BMD) loss after THA was compared with alendronate in a randomized controlled trial. Forty-eight patients were assigned to three groups, namely, the teriparatide, alendronate, and no medication groups.
Report a problemFND-2626078402
03HumanRandomized controlled trialEfficacy outcome
In patients after total hip arthroplasty, lumbar BMD was higher with teriparatide than alendronate at 48 weeks.
In plain wordsIn patients after hip replacement, lumbar bone density was higher with teriparatide than alendronate at 48 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar BMD at 48 weeks
Study
n: not reported in source
Comparator
Alendronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
On the other hand, higher lumbar BMD was observed in the teriparatide group than in the alendronate group at 48 weeks post-surgery.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effect of teriparatide for the prevention of bone mineral density (BMD) loss after THA was compared with alendronate in a randomized controlled trial. Forty-eight patients were assigned to three groups, namely, the teriparatide, alendronate, and no medication groups.
Report a problemFND-2626078403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT04167163

Abaloparatide Before Total Knee Arthroplasty

University of Wisconsin, Madisonn = 5810 Jan 2020 to 3 Apr 2025

Osteoporosis · Arthroplasties, Knee Replacement

Trial page ClinicalTrials.govUpdated 5 Jun 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.